|
시장보고서
상품코드
2106658
경피 약물전달 장치 : 시장 인사이트, 경쟁 구도 및 시장 예측(-2034년)Transdermal Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2034 |
||||||
DelveInsight
개요:
- 경피 약물 전달 장치 시장은 2025년에 757억 490만 달러로 추정되며, 2034년까지 1,352억 6,601만 달러에 달할 것으로 예측됩니다. 이러한 성장의 배경에는 전 세계 만성 질환 유병률 증가, 3세대 경피 기술의 도입 가속화, 그리고 통증 관리, 호르몬 요법, 심혈관 치료 분야에서 비침습적 치료법의 채택 확대가 있습니다.
- 전 세계 경피 약물 전달 기기 시장은 2026년부터 2034년까지의 예측 기간 동안 연평균 성장률(CAGR) 6.75%로 성장하고 있습니다.
- 유형별로는 2025년에 약물 함유 접착 패치 부문이 55.44%의 점유율을 차지하며 경피 약물 전달 기기 시장을 주도했습니다.
- 용도별로는 2025년에 통증 관리 부문이 추정 약 38%의 점유율을 차지하며 경피 약물 전달 기기 시장을 주도했습니다.
- 최종 사용자별로는 2025년에 병원 부문이 경피 약물 전달 기기 시장을 독점하며, 점유율은 약 52%로 추정됩니다.
- 북미는 2025년에 45.39%의 점유율로 전 세계 경피 약물 전달 장치 시장의 매출을 주도했으며, 예측 기간 동안 연평균 성장률(CAGR) 5.91%로 성장하여 전 세계적으로 가장 높은 지역 시장 점유율을 차지했습니다.
경피 약물 전달 장치는 비침습적 의료 기술로, 일반적으로 패치, 필름 또는 마이크로니들 시스템의 형태를 띠며, 피부를 통해 약물을 제어된 지속적 속도로 전신 순환계로 직접 전달하도록 설계되었습니다. 이러한 장치는 위장관에서의 분해나 간에서의 첫 통과 대사를 회피함으로써, 경구 투여나 주사 투여에 비해 안정적인 혈장 내 약물 농도를 유지하고, 환자의 복약 순응도를 향상시키며, 투여 빈도를 줄일 수 있습니다. 이 시장은 유형별로는 ‘약물 함유 접착 패치’, ‘매트릭스 패치’, ‘저장막 패치’, ‘마이크로니들 패치’로 분류되며, 용도별로는 ‘ 통증 관리', '중추신경계 질환', '호르몬 요법', '심혈관 질환' 등으로 분류되며, 최종 사용자별로는 '병원', '외래수술센터(ASC)' 등으로 분류됩니다. 만성 질환의 부담 증가, 보다 간편한 투여 경로를 선호하는 고령화 사회의 진전, 그리고 마이크로니들 어레이, 경피 흡수 촉진제, 커넥티드 ‘스마트’ 패치 분야의 급속한 기술 발전에 힘입어, 경피 약물 전달 장치는 진통제, 호르몬제, 심혈관계 약물 및 중추신경계 치료제의 투여에 있어 점점 더 선호되는 플랫폼이 되고 있습니다.
경피 약물 전달 장치 시장의 주요 시장 성장 촉진요인
- 당뇨병, 심혈관 질환, 만성 통증 등 만성 질환의 급속한 증가가 편의성이 높은 장기적인 경피 치료법에 대한 수요를 견인하고 있습니다.
- 마이크로니들, 나노 캐리어, 경피 흡수 촉진제, 신형 접착제 등의 기술적 진보로 인해 피부를 통해 전달 가능한 약물의 범위가 확대되고 있습니다.
- 비침습적이고 재택 치료를 선호하는 환자가 증가함에 따라, 주사나 병원 방문 횟수를 줄일 수 있는 패치 및 웨어러블 기기의 채택이 확대되고 있습니다.
- 센서 및 디지털 모니터링 기능을 통합한 ‘스마트’/커넥티드 패치의 등장으로, 개인 맞춤형 투여, 복약 순응도 추적, 원격 관리가 가능해졌습니다.
- 더 간편하고 침습성이 낮은 투여법을 선호하는 전 세계 고령화 추세가 시장의 지속적인 확장을 뒷받침하고 있습니다.
- 규제 당국의 승인 확대와 유리한 보험 환급 경로의 정비가 제조업체의 투자와 상품화를 뒷받침하고 있습니다.
- 통증이나 니코틴 이외의 분야, 즉 호르몬제, 심혈관계 약물, 백신, 생물학적 제제 등 분야로의 경피 투여 플랫폼 확대(특히 마이크로니들 시스템을 통한 것)로 인해 대상 시장이 확대되고 있습니다.
경피 약물 전달 기기 시장의 성장에 기여하는 요인
시장 성장 촉진요인
장기적인 약물 복용이 필요한 만성 질환의 급속한 증가
경피 약물 전달 기기 시장의 가장 일관된 촉진요인은 당뇨병, 심혈관 질환, 만성 통증 등 꾸준하고 장기적인 약물 복용이 필요한 만성 질환의 전 세계적 부담 증가입니다. 영국 심장 재단(2024년)에 따르면, 전 세계적으로 약 6억 2,000만 명, 즉 13명 중 1명의 비율로 심장 및 순환기 질환을 앓고 있으며, 관상동맥 질환은 전 세계적으로 약 2억 명에게 영향을 미치고 있습니다. 미국 질병통제예방센터(2024년) 보고서에 따르면, 2022년에는 성인의 약 4.9%가 관상동맥 질환으로 진단받았으며, 2023년까지 미국에서 약 1,210만 명이 심방세동을 앓을 것으로 예측됩니다. 경피 흡수형 의료기기는 항고혈압제, 협심증 치료제, 항응고제, 진통제를 제어된 속도로 투여하여 치료 성과와 환자의 복약 순응도를 향상시킵니다. 특히 고령화가 진행되고 앉아 있는 시간이 많은 생활 방식을 영위하는 인구가 증가하는 가운데, 만성 질환 유병률이 계속 상승함에 따라 경피 흡수형 투여 플랫폼에 대한 수요는 직접적으로 확대되어 2034년까지 시장 성장의 원동력이 될 것입니다.
3세대 경피 흡수 기술의 채택 확대
1세대 수동형 패치에서 마이크로니들 어레이, 이온토포레시스 및 일렉트로포레이션 지원형 기기, 첨단 화학적 증강제를 포함한 3세대 경피 흡수 시스템으로의 전환을 통해, 펩타이드, 생물학적 제제, 백신을 비롯한 피부를 통해 전달 가능한 분자의 범위가 확대되고 있습니다. 이러한 기술은 각질층이라는 천연 장벽을 극복하여, 기존에는 주사 경로로만 제한되었던 더 크고 복잡한 치료용 분자의 전달을 가능하게 하고 있습니다. 기기 제조업체와 제약 기업이 3세대 플랫폼의 상용화를 지속함에 따라, 통증 관리, 호르몬 요법, 심혈관 질환 치료 분야에서 채택이 가속화될 것으로 예상되며, 이는 시장의 지속적인 확장을 뒷받침할 전망입니다.
시장 성장 억제요인
강력한 성장세를 보이고 있음에도 불구하고, 경피 약물 전달 기기 시장은 중대한 제약에 직면해 있습니다. 부착 부위의 피부 자극, 홍반, 부종은 여전히 흔한 문제이며, 이는 환자의 복약 순응도를 저하시키고 제품 리콜 증가를 초래할 가능성이 있어 특정 제제의 채택을 억제하는 요인이 되고 있습니다. 분자 크기, 극성, 피부 투과성 등의 특성으로 인해 이 경로를 통해 효과적으로 투여할 수 있는 치료제의 범위가 제한되므로, 모든 약물 분자가 경피 투여에 적합한 것은 아닙니다. 이는 첨단 강화제나 마이크로니들 기술이 도입된 경우에도 마찬가지입니다. 2025년, FDA는 스코폴라민 패치와 관련된 열로 인한 과다 복용 위험에 대해 경고를 발령했으며, 이로 인해 표시 사항의 갱신이 촉구되는 한편, 이 범주와 관련된 지속적인 안전성 모니터링의 부담이 부각되었습니다. 또한, 의료기기 및 그 부품에 대한 수입 관세 부과로 인해 비용이 증가하고 기기 제조업체공급망이 혼란을 겪으면서, 조달처 및 제조 거점에 대한 전략적 재검토가 시급해졌습니다. 많은 패치의 경우, 일관된 투여량을 확보하거나 더 복잡한 분자에 대한 충분한 전신 흡수를 실현하는 것이 여전히 어렵기 때문에 업계 전반에 걸쳐 기술적 과제가 남아 있습니다. 이러한 안전성, 기술, 관세, 규제상의 장벽이 복합적으로 작용하여 성장 속도는 둔화되고 있지만, 한편으로는 만성 질환의 부담, 기술 혁신, 비침습적 치료를 선호하는 환자의 경향과 같은 근본적인 촉진요인은 여전히 확고합니다.
자주 묻는 질문
목차
제1장 경피 약물전달 장치 시장 : 서론
제2장 경피 약물전달 장치 시장 : 주요 요약
제3장 경피 약물전달 장치 시장 : 주요 요인 분석
제4장 AI, 지정학, 무역 및 경제 동향
제5장 규제 분석
제6장 Porter의 Five Forces 분석
제7장 경피 약물전달 장치 시장 : 평가
제8장 경피 약물전달 장치 시장 : 경쟁 구도
제9장 경피 약물전달 장치 시장 : 스타트업의 자금조달 및 투자 동향
제10장 경피 약물전달 장치 시장 : 기업 개요 및 제품 개요
제11장 KOL(Key Opinion Leader)의 견해
제12장 프로젝트 접근
제13장 DelveInsight에 대해
제14장 면책사항 및 문의
LSH 26.08.12Transdermal Drug Delivery Devices Market Summary
Overview:
- The Transdermal Drug Delivery Device market is estimated at USD 75,704.90 million in 2025 and is projected to reach USD 135,266.01 million by 2034. Growth is anchored in the rising global prevalence of chronic conditions, the accelerating shift toward third-generation transdermal technologies, and expanding non-invasive treatment adoption across pain management, hormonal, and cardiovascular therapy.
- The global Transdermal Drug Delivery Device market is growing at a CAGR of 6.75% during the forecast period from 2026 to 2034.
- By type, the drug-in-adhesive patches segment dominated the Transdermal Drug Delivery Device market with a 55.44% share in 2025.
- By application, the pain management segment dominated the Transdermal Drug Delivery Device market with an estimated ~38% share in 2025.
- By end-user, the hospitals segment dominated the Transdermal Drug Delivery Device market with an estimated ~52% share in 2025.
- North America dominated the global Transdermal Drug Delivery Device market revenue with a 45.39% share in 2025, growing at a CAGR of 5.91% during the forecast period, representing the highest regional market share globally.
A transdermal drug delivery device is a non-invasive medical technology, typically a patch, film, or microneedle system, designed to deliver medication through the skin directly into systemic circulation at a controlled and sustained rate. By bypassing gastrointestinal degradation and hepatic first-pass metabolism, these devices provide steady plasma drug concentrations, improved patient compliance, and reduced dosing frequency compared with oral or injectable routes. The market is organized by type across drug-in-adhesive patches, matrix patches, reservoir membrane patches, and microneedle patches; by application across pain management, central nervous system disorders, hormonal applications, cardiovascular disorders, and others; and by end-user across hospitals, ambulatory surgical centers, and others. Driven by the rising burden of chronic disease, an aging population that favors simpler administration routes, and rapid technological progress in microneedle arrays, skin-penetration enhancers, and connected "smart" patches, transdermal drug delivery devices have become an increasingly preferred platform for delivering analgesics, hormones, cardiovascular agents, and central nervous system therapeutics.
Transdermal Drug Delivery Devices Market Key Growth Drivers
- The rapid rise in chronic diseases such as diabetes, cardiovascular disease, and chronic pain is driving demand for convenient, long-term transdermal treatment options.
- Technological advances, including microneedles, nanocarriers, skin-penetration enhancers, and novel adhesives, are expanding the range of drugs deliverable through the skin.
- Growing patient preference for non-invasive, at-home care is increasing adoption of patches and wearables that reduce injections and hospital visits.
- The emergence of "smart"/connected patches integrating sensors and digital monitoring is enabling personalized dosing, adherence tracking, and remote care.
- An aging global population that favors simpler, less invasive administration is supporting sustained market uptake.
- An expanding wave of regulatory approvals and favorable reimbursement pathways is encouraging manufacturer investment and commercialization.
- Expansion of transdermal platforms beyond pain and nicotine into hormones, cardiovascular drugs, vaccines, and biologics, particularly via microneedle systems, is broadening the addressable market.
Key Companies in Transdermal Drug Delivery Devices Market
The competitive landscape is led by the following active device manufacturers:
- B Braun Meslungen AG
- BestMedical
- MINZE HEALTH
- Santron Meditronic.
- Potent Medical
- Laborie
- MEDKONSULT medical technology s.r.o.
- The Prometheus Group(R)
- HCItalia srl
- DeltaMed
Factors Contributing to the Growth of the Transdermal Drug Delivery Devices Market
Market Drivers
Rapid Rise in Chronic Diseases Requiring Long-Term Medication
The most consistent driver of the Transdermal Drug Delivery Device market is the growing global burden of chronic conditions that require steady, long-term medication, including diabetes, cardiovascular disease, and chronic pain. According to the British Heart Foundation (2024), approximately 620 million people worldwide, or about 1 in 13 individuals, live with heart and circulatory diseases, while coronary heart disease affects an estimated 200 million people globally. The U.S. Centers for Disease Control and Prevention (2024) reported that approximately 4.9% of adults were diagnosed with coronary heart disease in 2022, and an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation by 2023. Transdermal devices deliver antihypertensives, antianginal drugs, anticoagulants, and analgesics at a controlled rate, improving therapeutic outcomes and patient compliance. As the prevalence of chronic disease continues to rise, particularly among aging and increasingly sedentary populations, demand for transdermal delivery platforms expands directly, anchoring market growth through 2034.
Increasing Adoption of Third-Generation Transdermal Technologies
The transition from first-generation passive patches to third-generation transdermal systems, including microneedle arrays, iontophoretic and electroporation-assisted devices, and advanced chemical enhancers, is expanding the range of molecules that can be delivered through the skin, including peptides, biologics, and vaccines. These technologies overcome the natural barrier of the stratum corneum, enabling delivery of larger and more complex therapeutic molecules that were previously limited to injectable routes. As device makers and pharmaceutical sponsors continue to commercialize third-generation platforms, adoption is expected to accelerate across pain management, hormonal, and cardiovascular applications, reinforcing sustained market expansion.
Market Restraints
Despite strong momentum, the Transdermal Drug Delivery Device market faces material constraints. Skin irritation, erythema, and edema at the application site remain common limitations that can reduce patient adherence and prompt increased product recalls, tempering adoption of certain formulations. Not all drug molecules are suitable candidates for transdermal delivery, as molecular size, polarity, and skin-permeability characteristics restrict the range of therapeutics that can be effectively administered through this route, even with advanced enhancer and microneedle technologies. In 2025, the FDA issued a warning regarding heat-related overdose risk associated with scopolamine patches, prompting label updates and underscoring the ongoing safety-monitoring burden associated with the category. The imposition of import tariffs on medical devices and components has also increased costs and disrupted supply chains for device manufacturers, prompting strategic shifts in sourcing and manufacturing location. Technical challenges persist across the industry, as many patches continue to struggle with delivering consistent doses or achieving meaningful systemic absorption for more complex molecules. Together, these safety, technical, tariff, and regulatory barriers moderate the pace of growth, even as the underlying drivers of chronic disease burden, technological innovation, and patient preference for non-invasive care remain firmly intact.
Transdermal Drug Delivery Devices Market Segment Analysis
The Transdermal Drug Delivery Devices by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of World).
By Type
Dominant Subsegment: Drug-in-adhesive Patches.
Dominant: Drug-in-adhesive Patches ~ 55.44%
The drug-in-adhesive patches segment accounted for 55.44% of the Transdermal Drug Delivery Device market in 2025. Drug-in-adhesive patches are the leading type because the drug is directly incorporated into the adhesive layer, allowing a thin, low-profile design that is easy to apply, comfortable to wear, and does not require needles or invasive procedures. The adhesive layer both secures the patch to the skin and helps regulate the rate of drug release, providing controlled and consistent delivery over a prolonged period while maintaining stable plasma drug levels. The presence of established commercial products, including TRANSDERM-V by Novartis and the Mylan-rivastigmine Patch 10 by Viatris Inc., continues to reinforce category demand and clinical familiarity among prescribers. While microneedle patches are the fastest-growing type on the strength of their ability to deliver larger and more complex molecules, the manufacturing simplicity, cost efficiency, and broad clinical adoption of drug-in-adhesive designs secure the segment's leadership across the forecast period.
By Application
Dominant Subsegment: Pain Management.
Dominant: Pain Management ~ 38%
The pain management segment accounted for an estimated ~38% of the Transdermal Drug Delivery Device market in 2025. Pain management is the leading application because chronic pain affects a very large global patient population and transdermal analgesic patches, including opioid and non-opioid formulations, provide sustained, controlled-release relief while avoiding the peaks and troughs associated with oral dosing. Transdermal delivery also reduces gastrointestinal side effects and supports better adherence among patients requiring long-term pain control following surgery, cancer treatment, or chronic musculoskeletal conditions. Central nervous system disorders and hormonal applications are expanding steadily as patch-based delivery of donepezil, rivastigmine, and hormone-replacement formulations gains adoption, and cardiovascular disorders continue to benefit from nitroglycerin and antihypertensive patches. Nonetheless, the sheer scale of the global chronic pain population and the maturity of transdermal analgesic products secure pain management's leadership across the forecast period.
Transdermal Drug Delivery Devices Market Region Analysis
Dominant Region: North America
Dominant: North America ~ 45.39% (Largest)
North America accounted for 45.39% of the global Transdermal Drug Delivery Device market revenue in 2025, growing at a CAGR of 5.91% during the forecast period from 2026 to 2034, representing the highest regional market share globally. The region's dominance reflects the growing prevalence of chronic pain, central nervous system disorders, and cardiovascular disease, alongside a steady cadence of new product launches and strong research and development investment. According to the CDC (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022, and by 2023 an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation, while over 795,000 people experience a stroke each year. The Alzheimer's Association (2024) estimates approximately 6.9 million Americans aged 65 and older are living with Alzheimer's disease, and the Parkinson's Foundation (2022) reports nearly 90,000 new Parkinson's diagnoses annually in the United States, with prevalence expected to reach 1.2 million by 2030. This substantial and growing disease burden, combined with demand for patient-friendly solutions that improve adherence and reduce systemic side effects, is accelerating adoption of transdermal technologies. Product development activity continues to reinforce the region's leadership, including the February 2024 launch of the UDENYCA on-body injector by LTS Lohmann Therapie-Systeme AG through its Sorrel platform, which reduces infection risk following chemotherapy.
Fastest Growing Region: Asia-Pacific
Asia-Pacific is the fastest-growing region in the Transdermal Drug Delivery Device market. The region's elevated growth rate is driven by rising chronic disease incidence, rapidly expanding healthcare infrastructure, and growing manufacturing investment across China, Japan, India, South Korea, and Australia. China is scaling domestic transdermal manufacturing and secured its first NMPA-approved domestically produced rivastigmine patch in 2024 through Sino Biopharmaceutical; Japan continues to lead in advanced patch and microneedle innovation, South Korea's Daewoong launched its CLOPAM microneedle platform in 2024, and India offers competitive manufacturing economics that are attracting outsourced production. Rising healthcare expenditure, an expanding base of chronic disease patients, and growing local regulatory capability are accelerating adoption, while regional manufacturers scale quality systems to align with international GMP standards. The combination of high disease burden, manufacturing investment, and improving regulatory pathways positions Asia-Pacific as the principal source of incremental growth over the forecast period.
Regional Commentary
North America
North America accounted for 45.39% of the global Transdermal Drug Delivery Device market revenue in 2025. The United States dominates on the strength of its chronic disease burden, mature clinical infrastructure, FDA regulatory clarity, and steady cadence of product launches, with growing investment in smart-patch and microneedle innovation reinforcing regional leadership.
Europe
Europe is a large and technologically advanced regional market, supported by established EMA regulatory frameworks, a strong base of specialty pharmaceutical and device manufacturers, and rising adoption of hormonal and cardiovascular transdermal therapies across Germany, France, the United Kingdom, Italy, and Spain.
Asia-Pacific
Asia-Pacific is the fastest-growing region, propelled by rising chronic disease incidence, expanding healthcare infrastructure, and growing manufacturing investment across China, Japan, India, South Korea, and Australia, with regional regulatory approvals and microneedle innovation accelerating adoption.
Rest of World
The Rest of World region, spanning Latin America, the Middle East, and Africa, is an emerging growth frontier. Expanding healthcare access, rising demand for non-invasive chronic disease management, and gradual alignment of regulatory frameworks with global standards are broadening market access, while international partnerships support the build-out of regional distribution capacity.
Transdermal Drug Delivery Devices Market Competitive Landscape
The Transdermal Drug Delivery Device market is classified as Fragmented. A broad base of specialized device manufacturers and medical technology providers, including B Braun Meslungen AG, Laborie, and DeltaMed, compete alongside emerging and regionally focused players such as BestMedical, MINZE HEALTH, Santron Meditronic, Potent Medical, MEDKONSULT medical technology s.r.o., The Prometheus Group(R), and HCItalia srl, each pursuing differentiated positioning through device design, application-specific formulation support, and regional distribution reach.
The competitive landscape can be evaluated across the following dimensions:
- Market concentration: Fragmented, with a broad base of specialized device manufacturers competing alongside diversified medical technology providers.
- Leading players: B Braun Meslungen AG, Laborie, DeltaMed, and HCItalia srl anchor a competitive field of specialized transdermal and medical device manufacturers.
- Geographic reach: Leading providers maintain multi-country manufacturing and distribution networks across Europe and North America, supporting regional regulatory compliance and supply reliability.
- Product portfolio strength: Top players offer differentiated patch formats, adhesive technologies, and application-specific device design spanning pain management, hormonal, and cardiovascular indications.
- Manufacturing capabilities: GMP-compliant production facilities, quality-controlled adhesive and membrane processing, and scalable microneedle fabrication are key competitive differentiators.
- Innovation focus: Microneedle scale-up, smart and connected patch development, novel skin-penetration enhancers, and sustainable, low-waste manufacturing processes.
- Regulatory positioning: Providers with proven compliance records across FDA, EMA, and regional regulatory bodies are better positioned to win long-term supply agreements.
- Strategic partnerships: Collaboration with pharmaceutical sponsors and contract manufacturers to co-develop application-specific transdermal formulations is extending market reach.
Transdermal Drug Delivery Devices Market Recent Developmental Activities
In 2025, the FDA issued a safety communication regarding heat-related overdose risk associated with scopolamine transdermal patches, resulting in updated product labeling. Strategic significance: Reinforces the importance of safety monitoring and label compliance across the transdermal patch category.
In July 2024, Kindeva Drug Delivery had its Woodbury, Minnesota facility FDA-inspected and classified, expanding integrated and stand-alone analytical services for pharmaceutical, biopharmaceutical, and medical device clients. Strategic significance: Strengthens third-party analytical and manufacturing support capacity for transdermal device developers.
Transdermal Drug Delivery Devices Market Segmentation
Transdermal Drug Delivery Devices Market by Drug Type
- Drug-in-adhesive Patches
- Matrix Patches
- Reservoir Membrane Patches
- Microneedle Patches
Transdermal Drug Delivery Devices Market by Application
- Pain Management
- Central Nervous System Disorders
- Hormonal Applications
- Cardiovascular Disorders
- Others
Transdermal Drug Delivery Devices Market by End User
- Hospitals
- Ambulatory Surgical Centers
- Others
Transdermal Drug Delivery Devices Market by Geography
- North America Transdermal Drug Delivery Devices Market
- United States Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Canada Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Mexico Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Europe Transdermal Drug Delivery Devices Market
- Germany Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- United Kingdom Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- France Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Italy Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Spain Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Rest of Europe Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Asia-Pacific Transdermal Drug Delivery Devices Market
- China Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Japan Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- India Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Australia Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- South Korea Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Rest of Asia-Pacific Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Rest of the World (RoW) Transdermal Drug Delivery Devices Market
- Middle East Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- Africa Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- South America Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
Key Takeaways from the Transdermal Drug Delivery Devices Market Report Study
- Market size analysis for the current transdermal drug delivery devices market size (2025), and market forecast for 9 years (2026 to 2034).
- Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures that happened over the last 3 years.
- Key companies dominating the global transdermal drug delivery devices market.
- Various opportunities available for competitors in the transdermal drug delivery devices market space.
- What are the top-performing segments in 2025? How will these segments perform in 2034?
- Which are the top-performing regions and countries in the current transdermal drug delivery devices market scenario?
- Which are the regions and countries where companies should concentrate their opportunities for transdermal drug delivery devices market growth in the future?
Target audience who can benefit from this transdermal drug delivery devices market report study
- Transdermal drug delivery devices product providers
- Research organizations and consulting companies
- Transdermal drug delivery devices-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in transdermal drug delivery devices
- Various end-users who want to know more about the transdermal drug delivery devices market and the latest technological developments in the transdermal drug delivery devices market.
Frequently Asked Questions:
Q1. What is the growth rate of the Transdermal Drug Delivery Devices market?
The Transdermal Drug Delivery Devices market is projected to expand at a CAGR of 6.75% during the forecast period from 2026-2034.
Q2. What is the market size of the Transdermal Drug Delivery Devices market?
The Transdermal Drug Delivery Devices market is estimated at USD 75,704.90 million in 2025 and is projected to reach USD 135,266.01 million by 2034.
Q3. Which region dominates the Transdermal Drug Delivery Devices market?
North America dominated the Transdermal Drug Delivery Device market with a 45.39% share of global revenue in 2025, supported by the growing prevalence of chronic pain, central nervous system disorders, and cardiovascular disease, along with strong research and development activity and a steady cadence of new product launches. Asia-Pacific is the fastest-growing region over the forecast period.
Q4. What are the key drivers of the Transdermal Drug Delivery Devices market?
The principal drivers are the rapid rise in chronic diseases requiring long-term medication, increasing adoption of third-generation transdermal technologies, growing patient preference for non-invasive at-home care, the emergence of smart and connected patch technologies, an aging global population, and expanding regulatory approvals across pain management, central nervous system, hormonal, and cardiovascular applications.
Q5. Who are the major players in the Transdermal Drug Delivery Devices market?
The major players include B Braun Meslungen AG, BestMedical, MINZE HEALTH, Santron Meditronic, Potent Medical, Laborie, MEDKONSULT medical technology s.r.o., The Prometheus Group(R), HCItalia srl, DeltaMed, among other active providers profiled in the Competitive Landscape section. B Braun Meslungen AG, Laborie, DeltaMed, and HCItalia srl lead through broad device portfolios and multi-country manufacturing reach.
Table of Contents
1. Transdermal Drug Delivery Devices Market Report Introduction
- 1.1 Scope of the Study
- 1.2 Market Segmentation
- 1.3 Market Assumptions
2. Transdermal Drug Delivery Devices Market Executive Summary
- 2.1 Market at a Glance
3. Transdermal Drug Delivery Devices Market Key Factors Analysis
- 3.1 Transdermal Drug Delivery Devices Market Drivers
- 3.1.1 Rapid Rise in Chronic Diseases
- 3.1.2 Increasing Adoption of Third-Generation Technologies
- 3.1.3 Patient Preference for Non-Invasive, At-Home Care
- 3.1.4 Growth of Smart and Connected Patch Technologies
- 3.2 Transdermal Drug Delivery Devices Market Restraints and Challenges
- 3.2.1 Skin Irritation, Edema, and Product Recalls
- 3.2.2 Molecular and Technical Delivery Limitations
- 3.2.3 Tariff and Supply Chain Complexity
- 3.3 Transdermal Drug Delivery Devices Market Opportunities
- 3.3.1 Microneedle and Macromolecule Delivery Scale-Up
- 3.3.2 Emerging-Market and Smart Patch Expansion
4. Impact Analysis: AI, Geopolitical, Trade, and Economic Developments
5. Regulatory Analysis
- 5.1 United States
- 5.2 Europe
- 5.3 Japan
- 5.4 China
6. Transdermal Drug Delivery Devices Market Porter's Five Forces Analysis
- 6.1 Bargaining Power of Suppliers
- 6.2 Bargaining Power of Buyers
- 6.3 Threat of New Entrants
- 6.4 Threat of Substitutes
- 6.5 Competitive Rivalry
7. Transdermal Drug Delivery Devices Market Assessment
- 7.1 By Type
- 7.1.1 Drug-in-adhesive Patches
- 7.1.2 Matrix Patches
- 7.1.3 Reservoir Membrane Patches
- 7.1.4 Microneedle Patches
- 7.2 By Application
- 7.2.1 Pain Management
- 7.2.2 Central Nervous System Disorders
- 7.2.3 Hormonal Applications
- 7.2.4 Cardiovascular Disorders
- 7.2.5 Others
- 7.3 By End-User
- 7.3.1 Hospitals
- 7.3.2 Ambulatory Surgical Centers
- 7.3.3 Others
- 7.4 By Geography
- 7.4.1 North America
- 7.4.1.1 United States Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.1.2 Canada Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.1.3 Mexico Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.2 Europe
- 7.4.2.1 Germany Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.2.2 United Kingdom Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.2.3 France Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.2.4 Italy Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.2.5 Spain Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.2.6 Rest of Europe Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.3 Asia-Pacific
- 7.4.3.1 China Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.3.2 Japan Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.3.3 India Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.3.4 Australia Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.3.5 South Korea Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.3.6 Rest of Asia-Pacific Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.4 Rest of World
- 7.4.4.1 Middle East Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.4.2 Africa Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.4.3 South America Transdermal Drug Delivery Devices Market Size in USD million (2023-2034)
- 7.4.1 North America
8. Transdermal Drug Delivery Devices Market Competitive Landscape
- 8.1 Market Concentration and Structure
- 8.2 Competitive Positioning and Market Share Analysis (Premium Offering)
9. Transdermal Drug Delivery Devices Market Startup Funding and Investment Trends
10. Transdermal Drug Delivery Devices Market Company and Product Profiles
- 10.1 B Braun Meslungen AG
- 10.1.1 Company Overview
- 10.1.2 Company Snapshot
- 10.1.3 Financial Overview
- 10.1.4 Service Portfolio
- 10.1.5 Strategic Initiatives / Entropy
- 10.2 BestMedical
- 10.2.1 Company Overview
- 10.2.2 Company Snapshot
- 10.2.3 Financial Overview
- 10.2.4 Product Portfolio
- 10.2.5 Strategic Initiatives / Entropy
- 10.3 MINZE HEALTH
- 10.3.1 Company Overview
- 10.3.2 Company Snapshot
- 10.3.3 Financial Overview
- 10.3.4 Product Portfolio
- 10.3.5 Strategic Initiatives / Entropy
- 10.4 Santron Meditronic
- 10.4.1 Company Overview
- 10.4.2 Company Snapshot
- 10.4.3 Financial Overview
- 10.4.4 Product Portfolio
- 10.4.5 Strategic Initiatives / Entropy
- 10.5 Potent Medical
- 10.5.1 Company Overview
- 10.5.2 Company Snapshot
- 10.5.3 Financial Overview
- 10.5.4 Product Portfolio
- 10.5.5 Strategic Initiatives / Entropy
- 10.6 Laborie
- 10.6.1 Company Overview
- 10.6.2 Company Snapshot
- 10.6.3 Financial Overview
- 10.6.4 Product Portfolio
- 10.6.5 Strategic Initiatives / Entropy
- 10.7 MEDKONSULT medical technology s.r.o.
- 10.7.1 Company Overview
- 10.7.2 Company Snapshot
- 10.7.3 Financial Overview
- 10.7.4 Product Portfolio
- 10.7.5 Strategic Initiatives / Entropy
- 10.8 The Prometheus Group(R)
- 10.8.1 Company Overview
- 10.8.2 Company Snapshot
- 10.8.3 Financial Overview
- 10.8.4 Product Portfolio
- 10.8.5 Strategic Initiatives / Entropy
- 10.9 HCItalia srl
- 10.9.1 Company Overview
- 10.9.2 Company Snapshot
- 10.9.3 Financial Overview
- 10.9.4 Product Portfolio
- 10.9.5 Strategic Initiatives / Entropy
- 10.10 DeltaMed
- 10.10.1 Company Overview
- 10.10.2 Company Snapshot
- 10.10.3 Financial Overview
- 10.10.4 Product Portfolio
- 10.10.5 Strategic Initiatives / Entropy
For illustrative purposes, only the top 10 companies are listed in the Table of Contents. The report may include analysis and references to additional companies where relevant to the market assessment.
